

# PHARMACOECONOMIC ANALYSIS OF THE STANDARD THE TREATMENT AND CARE OF PEOPLE WITH HYPERTENSION

A. A. Leontyeva , N. V. Bezditko

The National University of Pharmacy, Kharkiv, Ukraine

High blood pressure (hypertension) is a serious condition that can lead to coronary heart disease, heart failure, stroke, kidney failure, and other health problems. In Ukraine there are clinical guidelines and standard for the treatment and care of people with hypertension.

The purpose of the study is the determination of the range of the cost of pharmacotherapy of hypertension stage II according to the national standard of care.

Materials: standard for the treatment and care of people with hypertension, State Formulary of Ukraine. Methods: pharmacoeconomic methods of the total cost of illness and cost-minimization analysis.

Results. There are 5 pharmacological groups in the national standard of pharmacotherapy of hypertension:  $\beta$ -blockers, thiazide diuretics, ACE inhibitors, angiotensin receptor II inhibitors, calcium antagonists. According to the State Formulary there are 9 INN  $\beta$ -blockers (71 trade name – 21 of them are drug domestically produced and imported 50 drugs), 2 INN thiazide diuretics (19 trade name – 4 of them domestic and 15 imported drugs), 10 INN ACE inhibitors (71 trade name – 15 of them domestic and 56 imported drugs), 7 INN angiotensin receptor II inhibitors (42 trade name – 6 of them domestic and 36 imported drugs), 5 INN calcium antagonists (50 trade name – 14 of them domestic and 36 imported drugs).

Cost of monotherapy within one year depends on the chosen drug. Lowest cost of treatment lowest cost of treatment the case using:  $\beta$ -blocker Atenolol-Astrafarm ("Astrafarm", Ukraine); ACE inhibitor Enalapril ("Lubnyfarm", Ukraine); ARB Kasark ("Kievmedpreparat", Ukraine); a calcium channel blocker Amlodipine-Astrafarm ("Astrafarm", Ukraine); thiazides Hydrochlorothiazide ("Borschagovsky CPP", Ukraine). The most expensive cost of treatment:  $\beta$ -blocker Nebival ("Kiev Vitamin Plant", Ukraine); ACE inhibitor Captopril ("Kievmedpreparat", Ukraine), ARB Kasark ("Kievmedpreparat", Ukraine); a calcium channel blocker Felodip («TEVA» Czech Republic); thiazides Hydrochlorothiazide ("Chinoi", Hungary).

Conclusions: Ukrainian pharmaceutical market provides real opportunities for choice of antihypertensive drugs for patients with a variety of economic opportunities. Depending on the choice of drugs difference in treatment price is nine times.